WO1986004356A1
(en)
|
1985-01-28 |
1986-07-31 |
International Genetic Engineering, Inc. |
AraB PROMOTERS AND METHOD OF PRODUCING POLYPEPTIDES, INCLUDINN CECROPINS, BY MICROBIOLOGICAL TECHNIQUES
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
IN165717B
(en)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
US5202238A
(en)
|
1987-10-27 |
1993-04-13 |
Oncogen |
Production of chimeric antibodies by homologous recombination
|
US6004781A
(en)
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
IL86278A
(en)
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5216132A
(en)
|
1990-01-12 |
1993-06-01 |
Protein Design Labs, Inc. |
Soluble t-cell antigen receptor chimeric antigens
|
US20020004052A1
(en)
|
1990-05-08 |
2002-01-10 |
David Berd |
Composition comprising a tumor cell extract and method of using the composition
|
US5914109A
(en)
|
1990-06-15 |
1999-06-22 |
New York University |
Heterohybridomas producing human monoclonal antibodies to HIV-1
|
EP0517895B1
(en)
|
1990-12-14 |
1996-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6407221B1
(en)
|
1990-12-14 |
2002-06-18 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US20020111474A1
(en)
|
1990-12-14 |
2002-08-15 |
Capon Daniel J. |
Chimeric chains for receptor-associated signal transduction pathways
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
US5843728A
(en)
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
IE920716A1
(en)
|
1991-03-07 |
1992-09-09 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
EP0575537A1
(en)
|
1991-03-08 |
1993-12-29 |
Cytomed, Inc. |
Soluble cd28 proteins and methods of treatment therewith
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
CA2121487A1
(en)
|
1991-10-21 |
1993-04-29 |
Stephen A. Sherwin |
Combined cellular and immunosuppresive therapies
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
US5372930A
(en)
|
1992-09-16 |
1994-12-13 |
The United States Of America As Represented By The Secretary Of The Navy |
Sensor for ultra-low concentration molecular recognition
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
ES2276390T3
(en)
|
1992-11-05 |
2007-06-16 |
Sloan-Kettering Institute For Cancer Research |
SPECIFIC MEMBRANE ANTIGEN OF THE PROSTATE.
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
WO1994022914A1
(en)
|
1993-04-06 |
1994-10-13 |
Fred Hutchinson Cancer Research Center |
Chimeric cytokine receptors in lymphocytes
|
US6051427A
(en)
|
1993-06-11 |
2000-04-18 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
US5834256A
(en)
|
1993-06-11 |
1998-11-10 |
Cell Genesys, Inc. |
Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
|
US5525503A
(en)
|
1993-09-28 |
1996-06-11 |
Dana-Farber Cancer Institute, Inc. |
Signal transduction via CD28
|
US5935818A
(en)
|
1995-02-24 |
1999-08-10 |
Sloan-Kettering Institute For Cancer Research |
Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
|
ES2185705T3
(en)
|
1994-05-02 |
2003-05-01 |
Bernd Groner |
BIFUNCTIONAL PROTEIN, PREPARATION AND USE.
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
US7354587B1
(en)
|
1994-07-06 |
2008-04-08 |
Immunomedics, Inc. |
Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
|
US5716614A
(en)
|
1994-08-05 |
1998-02-10 |
Molecular/Structural Biotechnologies, Inc. |
Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
|
WO1996013584A1
(en)
|
1994-11-01 |
1996-05-09 |
Targeted Genetics Corporation |
Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
|
US5741899A
(en)
|
1995-02-02 |
1998-04-21 |
Cell Genesys, Inc. |
Chimeric receptors comprising janus kinase for regulating cellular pro liferation
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
DE69635801T2
(en)
|
1995-02-24 |
2006-11-02 |
Sloan-Kettering Institute For Cancer Research |
PROSTATE-SPECIFIC MEMBRANES ANTIGEN AND ITS APPLICATIONS
|
US5830755A
(en)
|
1995-03-27 |
1998-11-03 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
T-cell receptors and their use in therapeutic and diagnostic methods
|
WO1997004752A1
(en)
|
1995-07-26 |
1997-02-13 |
Duramed Pharmaceuticals, Inc. |
Pharmaceutical compositions of conjugated estrogens and methods for their use
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
US6261787B1
(en)
|
1996-06-03 |
2001-07-17 |
Case Western Reserve University |
Bifunctional molecules for delivery of therapeutics
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
US20020018783A1
(en)
|
1997-03-20 |
2002-02-14 |
Michel Sadelain |
Fusion proteins of a single chain antibody and cd28 and uses thereof
|
WO1998056924A1
(en)
|
1997-06-11 |
1998-12-17 |
New York University |
Prenylcysteine carboxyl methyltransferase, dna encoding same, and a method of screening for inhibitors thereof
|
US6759243B2
(en)
|
1998-01-20 |
2004-07-06 |
Board Of Trustees Of The University Of Illinois |
High affinity TCR proteins and methods
|
US20090011984A1
(en)
|
1998-02-23 |
2009-01-08 |
Seppo Yla-Herttuala |
Biotin-binding receptor molecules
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
PT1066380E
(en)
|
1998-05-19 |
2002-05-31 |
Avidex Ltd |
T SOLUVEL CELL RECEIVER
|
JP2002524081A
(en)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
Fusion receptor specific for prostate-specific membrane antigen and uses thereof
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
ES2293748T3
(en)
|
1998-10-21 |
2008-03-16 |
Altor Bioscience Corporation |
POLYPE SPECIFIC FOLATION MOLECULES AND USES OF THE SAME.
|
US7217421B1
(en)
|
1998-11-03 |
2007-05-15 |
Cell Genesys, Inc. |
Cancer-associated antigens and methods of their identification and use
|
US6521602B1
(en)
|
1999-03-01 |
2003-02-18 |
Gpc Biotech Inc. |
Anti-neoplastic compositions and uses thereof
|
EP1171596A1
(en)
|
1999-04-16 |
2002-01-16 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
US6699972B1
(en)
|
1999-06-25 |
2004-03-02 |
Academia Sinica |
Chimeric protein and method of controlling tumor growth using the protein
|
US7569663B2
(en)
|
2000-01-03 |
2009-08-04 |
Mark L. Tykocinski |
Chimeric proteins and methods for using the same
|
WO2001060317A2
(en)
|
2000-02-14 |
2001-08-23 |
The Regents Of The University Of California |
Kidney-specific tumor vaccine directed against kidney tumor antigen g-250
|
US6770749B2
(en)
|
2000-02-22 |
2004-08-03 |
City Of Hope |
P53-specific T cell receptor for adoptive immunotherapy
|
JP5059271B2
(en)
|
2000-03-31 |
2012-10-24 |
パーデュー・リサーチ・ファウンデイション |
Treatment methods using ligand immunogen complexes
|
AU2001255580A1
(en)
|
2000-04-21 |
2001-12-11 |
Rutgers, The State University Of New Jersey |
Methods and compositions for the diagnosis of schizophrenia
|
US6524572B1
(en)
|
2000-06-26 |
2003-02-25 |
Rainbow Therapeutic Company |
Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
|
DE60133287T2
(en)
|
2000-07-31 |
2009-03-26 |
Green Peptide Co., Ltd., Kurume |
TUMOR ANTIGEN
|
US7666424B2
(en)
|
2001-10-17 |
2010-02-23 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparing and using single chain anti-tumor antibodies
|
EP1334188B1
(en)
|
2000-11-07 |
2006-08-30 |
City of Hope |
Cd19-specific redirected immune cells
|
US20020132983A1
(en)
|
2000-11-30 |
2002-09-19 |
Junghans Richard P. |
Antibodies as chimeric effector cell receptors against tumor antigens
|
US7723111B2
(en)
|
2001-03-09 |
2010-05-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Activated dual specificity lymphocytes and their methods of use
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
AU2002256390B2
(en)
|
2001-04-30 |
2007-08-30 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US20070031438A1
(en)
|
2001-12-10 |
2007-02-08 |
Junghans Richard P |
Antibodies as chimeric effector cell receptors against tumor antigens
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
AU2003256912A1
(en)
|
2002-08-16 |
2004-03-03 |
Yeda Research And Development Co. Ltd. |
Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
DE10244457A1
(en)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Process for the rational mutagenesis of alpha / beta T-cell receptors and corresponding mutated MDM2 protein-specific alpha / beta T-cell receptors
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
US20060018878A1
(en)
|
2003-03-11 |
2006-01-26 |
City Of Hope |
Dual antigen specific T cells with trafficking ability
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
US20130266551A1
(en)
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
WO2005079836A1
(en)
|
2004-02-18 |
2005-09-01 |
Wisconsin Alumni Research Foundation |
Method for treating glaucoma
|
CA2557698A1
(en)
|
2004-03-02 |
2005-09-15 |
Cellectar, Llc |
Phospholipid analogs as diapeutic* agents and methods therefor
|
CA3052445C
(en)
|
2004-07-10 |
2023-08-22 |
Kerry S. Campbell |
Genetically modified human natural killer cell lines
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
US7994298B2
(en)
|
2004-09-24 |
2011-08-09 |
Trustees Of Dartmouth College |
Chimeric NK receptor and methods for treating cancer
|
AU2005336093B2
(en)
|
2004-10-08 |
2011-02-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Adoptive immunotherapy with enhanced T lymphocyte survival
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
EP1979379B1
(en)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
US7919079B2
(en)
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
EP1900752A1
(en)
|
2006-09-15 |
2008-03-19 |
DOMPE' pha.r.ma s.p.a. |
Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
US9334330B2
(en)
|
2006-10-10 |
2016-05-10 |
Universite De Nantes |
Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
|
US8685752B2
(en)
|
2006-11-03 |
2014-04-01 |
Purdue Research Foundation |
Ex vivo flow cytometry method and device
|
AU2007319881B2
(en)
|
2006-11-13 |
2012-05-17 |
Sangamo Therapeutics, Inc. |
Zinc finger nuclease for targeting the human glucocorticoid receptor locus
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
US8748405B2
(en)
|
2007-01-26 |
2014-06-10 |
City Of Hope |
Methods and compositions for the treatment of cancer or other diseases
|
WO2008093688A1
(en)
|
2007-01-30 |
2008-08-07 |
Forerunner Pharma Research Co., Ltd. |
CHIMERIC Fcγ RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
|
DK2126054T3
(en)
|
2007-01-31 |
2016-10-03 |
Yeda Res & Dev |
REROUTED, GENETICALLY MODIFIED regulatory T cells and their use for suppressing autoimmune inflammatory disease AND
|
WO2008097926A2
(en)
|
2007-02-02 |
2008-08-14 |
Yale University |
Transient transfection with rna
|
US8865169B2
(en)
|
2007-02-20 |
2014-10-21 |
Tufts University |
Methods and systems for multi-antibody therapies
|
CA2967847C
(en)
|
2007-03-30 |
2023-08-01 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
US20110269942A1
(en)
|
2007-08-09 |
2011-11-03 |
Daiichi Sankyo Company, Limited |
Antibodies modified with hydrophobic molecule
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
WO2009117117A1
(en)
|
2008-03-19 |
2009-09-24 |
Altor Bioscience Corporation |
T cell receptor fusions and conjugates and methods of use there of
|
US8450112B2
(en)
|
2008-04-09 |
2013-05-28 |
Maxcyte, Inc. |
Engineering and delivery of therapeutic compositions of freshly isolated cells
|
WO2009126944A1
(en)
|
2008-04-11 |
2009-10-15 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
US20090324630A1
(en)
|
2008-04-21 |
2009-12-31 |
Jensen Michael C |
Fusion multiviral chimeric antigen
|
PL3006459T3
(en)
|
2008-08-26 |
2022-01-17 |
City Of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
JP5675619B2
(en)
|
2008-09-17 |
2015-02-25 |
エンドサイト, インク.Endocyte, Inc. |
Folate antagonist binding conjugate of folate antagonist
|
CN104195227B
(en)
|
2008-11-07 |
2017-04-12 |
适应生物技术公司 |
Methods of monitoring conditions by sequence analysis
|
WO2010059253A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
US20110178279A1
(en)
|
2009-08-03 |
2011-07-21 |
Williams John C |
Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
|
WO2010132532A1
(en)
|
2009-05-15 |
2010-11-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
B cell surface reactive antibodies
|
US20100322909A1
(en)
|
2009-06-17 |
2010-12-23 |
The University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Th1-associated micrornas and their use for tumor immunotherapy
|
WO2011041093A1
(en)
|
2009-10-01 |
2011-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
CN102597222B
(en)
|
2009-10-27 |
2015-07-15 |
因缪尼卡姆股份公司 |
Method for proliferation of antigen-specific T cells
|
US9273283B2
(en)
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
US9181527B2
(en)
|
2009-10-29 |
2015-11-10 |
The Trustees Of Dartmouth College |
T cell receptor-deficient T cell compositions
|
TR201904484T4
(en)
|
2009-11-03 |
2019-05-21 |
Hope City |
Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection.
|
CN102762719A
(en)
|
2009-12-08 |
2012-10-31 |
威尔森沃尔夫制造公司 |
Improved methods of cell culture for adoptive cell therapy
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
IN2012DN06629A
(en)
|
2010-01-28 |
2015-10-23 |
Philadelphia Children Hospital |
|
AU2011212794B2
(en)
|
2010-02-04 |
2014-06-26 |
The Trustees Of The University Of Pennsylvania |
ICOS critically regulates the expansion and function of inflammatory human Th17 cells
|
AU2011215685B2
(en)
|
2010-02-12 |
2015-08-20 |
Oncomed Pharmaceuticals, Inc. |
Methods for identifying and isolating cells expressing a polypeptide
|
SA111320200B1
(en)
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
|
US9833480B2
(en)
|
2010-04-14 |
2017-12-05 |
Prospect Chartercare, Llc |
Methods and compositions for treating HIV
|
ES2686424T5
(en)
|
2010-05-04 |
2023-03-27 |
Yeda Res & Dev |
Redirected allogeneic cell immunotherapy
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
WO2012012695A2
(en)
|
2010-07-23 |
2012-01-26 |
Fred Hutchinson Cancer Research Center |
A method for the treatment of obesity
|
DE102010036122A1
(en)
|
2010-09-01 |
2012-03-01 |
Nora Systems Gmbh |
Flooring
|
EP2614151B1
(en)
|
2010-09-08 |
2019-07-24 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Interleukin 15 as selectable marker for gene transfer in lymphocytes
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
WO2012031744A1
(en)
|
2010-09-08 |
2012-03-15 |
Chemotherapeutisches Forschungsinstitut |
Chimeric antigen receptors with an optimized hinge region
|
CN103124740B
(en)
|
2010-09-21 |
2015-09-02 |
美国卫生和人力服务部 |
Anti-SSX-2T cell receptor and associated materials and using method
|
US9267164B2
(en)
|
2010-09-26 |
2016-02-23 |
Da Yu Enterprises, L.L.C. |
Method of recombinant macromolecular production
|
US9845362B2
(en)
|
2010-10-08 |
2017-12-19 |
The University Of North Carolina At Charlotte |
Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
PT3214091T
(en)
|
2010-12-09 |
2019-01-11 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
WO2012076059A1
(en)
|
2010-12-09 |
2012-06-14 |
Stichting Het Nederlands Kanker Instituut |
Immune restricted peptides with increased efficacy
|
ES2791716T3
(en)
|
2010-12-14 |
2020-11-05 |
Univ Maryland |
T cells expressing the universal anti-label chimeric antigen receptor and methods for the treatment of cancer
|
KR20140004174A
(en)
|
2011-01-18 |
2014-01-10 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Compositions and methods for treating cancer
|
SG10201602159VA
(en)
|
2011-02-11 |
2016-04-28 |
Sloan Kettering Inst Cancer |
Hla-restricted, peptide-specific antigen binding proteins
|
BR112013024395B1
(en)
|
2011-03-23 |
2021-10-26 |
Fred Hutchinson Cancer Research Center |
ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
|
EP2502934B1
(en)
|
2011-03-24 |
2018-01-17 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
|
EP3323833B1
(en)
|
2011-04-01 |
2019-12-04 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
|
CN103596981B
(en)
|
2011-04-08 |
2017-06-16 |
美国卫生和人力服务部 |
Anti-epidermal growth factor receptor variant III Chimeric antigen receptors and its purposes for treating cancer
|
KR20140043340A
(en)
|
2011-04-13 |
2014-04-09 |
이뮤니쿰 에이비 |
Method for priming of t cells
|
EP2697367B1
(en)
|
2011-04-13 |
2018-12-19 |
Immunicum AB |
Method for proliferation of antigen-specific t cells
|
EP2998320B1
(en)
|
2011-04-19 |
2018-07-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
GB201108236D0
(en)
|
2011-05-17 |
2011-06-29 |
Ucl Business Plc |
Method
|
WO2013019615A2
(en)
|
2011-07-29 |
2013-02-07 |
The Trustees Of The University Of Pennsylvania |
Switch costimulatory receptors
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
EP3392270B1
(en)
|
2011-09-15 |
2020-08-26 |
The United States of America, as Represented by the Secretary Department of Health and Human Services |
T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
EP2756521A4
(en)
|
2011-09-16 |
2015-04-22 |
Univ Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
WO2013044225A1
(en)
|
2011-09-22 |
2013-03-28 |
The Trustees Of The University Of Pennsylvania |
A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
|
US9175308B2
(en)
|
2011-10-07 |
2015-11-03 |
Mie University |
Chimeric antigen receptor
|
RU2644243C2
(en)
|
2011-10-20 |
2018-02-08 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Chimeric antigenic receptors to cd22
|
KR101471647B1
(en)
|
2011-10-26 |
2014-12-11 |
국립암센터 |
Mutant CTLA4 gene modified T-cell and composition for anticancer immunotherapy comprising thereof
|
WO2013063019A1
(en)
|
2011-10-28 |
2013-05-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
EP2773651B1
(en)
|
2011-11-03 |
2020-12-23 |
The Trustees of the University of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
CN104080797A
(en)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
Cyclin A1-targeted T-cell immunotherapy for cancer
|
CN104080462B
(en)
|
2011-12-16 |
2019-08-09 |
塔尔盖特基因生物技术有限公司 |
For modifying the composition and method of scheduled target nucleic acid sequence
|
US11147852B2
(en)
|
2011-12-23 |
2021-10-19 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
US20140370012A1
(en)
|
2012-01-27 |
2014-12-18 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
CA2864489C
(en)
|
2012-02-22 |
2023-08-08 |
The Trustees Of The University Of Pennsylvania |
Use of the cd2 signaling domain in second-generation chimeric antigen receptors
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
CA2864688C
(en)
|
2012-02-22 |
2023-09-05 |
The Trustees Of The University Of Pennsylvania |
Use of icos-based cars to enhance antitumor activity and car persistence
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CN104379179A
(en)
|
2012-04-11 |
2015-02-25 |
美国卫生和人力服务部 |
Chimeric antigen receptors targeting b-cell maturation antigen
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
US9751928B2
(en)
|
2012-05-03 |
2017-09-05 |
Fred Hutchinson Cancer Research Center |
Enhanced affinity T cell receptors and methods for making the same
|
US9790278B2
(en)
|
2012-05-07 |
2017-10-17 |
The Trustees Of Dartmouth College |
Anti-B7-H6 antibody, fusion proteins, and methods of using the same
|
IN2014MN02574A
(en)
|
2012-05-22 |
2015-07-24 |
Genentech Inc |
|
ES2835200T3
(en)
|
2012-05-22 |
2021-06-22 |
Us Health |
Medical use of cells comprising anti-NY-ESO-1 T cell receptors
|
EP3279315A3
(en)
|
2012-05-25 |
2018-02-28 |
Cellectis |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
WO2013181543A1
(en)
|
2012-06-01 |
2013-12-05 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
JP6421371B2
(en)
|
2012-06-08 |
2018-11-14 |
学校法人近畿大学 |
Antibodies against transporters and uses thereof
|
JP5863585B2
(en)
|
2012-07-11 |
2016-02-16 |
三菱電機株式会社 |
Transistor characteristic calculation device using large signal equivalent circuit model
|
CN104427997B
(en)
|
2012-07-13 |
2020-12-11 |
宾夕法尼亚大学董事会 |
Toxicity management of antitumor Activity of CARS
|
WO2014011988A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
EP3584256A1
(en)
|
2012-07-13 |
2019-12-25 |
The Trustees Of The University Of Pennsylvania |
Methods of assessing the suitability of transduced t cells for administration
|
CN104507537A
(en)
|
2012-07-13 |
2015-04-08 |
宾夕法尼亚大学董事会 |
Compositions and methods for regulating car t cells
|
CN102775500A
(en)
|
2012-08-03 |
2012-11-14 |
郑骏年 |
Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof
|
BR112015002816A8
(en)
|
2012-08-20 |
2023-04-18 |
Hutchinson Fred Cancer Res |
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
|
WO2014031476A1
(en)
|
2012-08-21 |
2014-02-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
JP6352920B2
(en)
|
2012-09-04 |
2018-07-04 |
セレクティス |
Multi-chain chimeric antigen receptor and uses thereof
|
US9879065B2
(en)
|
2012-09-14 |
2018-01-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors recognizing MHC class II-restricted MAGE-A3
|
ES2666131T3
(en)
|
2012-09-27 |
2018-05-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods to cause potent antitumor activity
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
CA2886859C
(en)
|
2012-10-02 |
2022-05-17 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for immunotherapy
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
EP2906684B8
(en)
|
2012-10-10 |
2020-09-02 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
WO2014059248A1
(en)
|
2012-10-12 |
2014-04-17 |
Philadelphia Health & Education Corporation D/B/A/ Drexel |
Mir-155 enhancement of cd8+ t cell immunity
|
UY35103A
(en)
|
2012-10-29 |
2014-05-30 |
Glaxo Group Ltd |
2-REPLACED CEFEM COMPOUNDS
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
WO2014099671A1
(en)
|
2012-12-20 |
2014-06-26 |
Bluebird Bio, Inc. |
Chimeric antigen receptors and immune cells targeting b cell malignancies
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
AU2014214850C1
(en)
|
2013-02-06 |
2018-12-06 |
Celgene Corporation |
Modified T lymphocytes having improved specificity
|
JO3529B1
(en)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
|
CN110423282B
(en)
|
2013-02-15 |
2023-09-08 |
加利福尼亚大学董事会 |
Chimeric antigen receptor and methods of use thereof
|
ES2760023T3
(en)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Cancer treatment using humanized anti-EGFRvIII chimeric antigen receptor
|
TW201446794A
(en)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
SG11201506974XA
(en)
|
2013-03-14 |
2015-10-29 |
Bellicum Pharmaceuticals Inc |
Methods for controlling t cell proliferation
|
US9402888B2
(en)
|
2013-03-14 |
2016-08-02 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for treating cancer
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US20160017058A1
(en)
|
2013-03-14 |
2016-01-21 |
The California Institute For Biomedical Research |
Bispecific antibodies and uses thereof
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
US9393268B2
(en)
|
2013-03-15 |
2016-07-19 |
Thomas Jefferson University |
Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
|
CN105518018B
(en)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
Modified T lymphocytes
|
US9561291B2
(en)
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
TWI654206B
(en)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
KR102452767B1
(en)
|
2013-05-14 |
2022-10-12 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Human application of engineered chimeric antigen receptor (car) t-cells
|
EP3730615A3
(en)
|
2013-05-15 |
2020-12-09 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
EP3004168A4
(en)
|
2013-05-24 |
2017-03-01 |
Board of Regents, The University of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
ES2883131T3
(en)
|
2013-05-29 |
2021-12-07 |
Cellectis |
Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
|
DK3309248T3
(en)
|
2013-05-29 |
2021-08-02 |
Cellectis |
Method for manipulating T cells for immunotherapy using an RNA-guided CAS nuclease system
|
EP3569253A1
(en)
|
2013-06-05 |
2019-11-20 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
WO2014200891A1
(en)
|
2013-06-11 |
2014-12-18 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES |
Her2-specific monoclonal antibodies and conjugates thereof
|
DK3013350T3
(en)
|
2013-06-25 |
2020-04-14 |
Vaccinex Inc |
Use of semaphorin 4D inhibitory molecules in combination with an immunomodulatory therapy to inhibit tumor growth and metastases
|
AU2014312119B2
(en)
|
2013-08-30 |
2019-09-19 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
EP3044196A4
(en)
|
2013-09-11 |
2017-05-24 |
Equip, LLC |
Discrete peg based dyes
|
CA2925393C
(en)
|
2013-10-11 |
2023-03-07 |
Dimiter Dimitrov |
Tem8 antibodies and their use
|
WO2015057852A1
(en)
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Chimeric antigen receptor t cell switches and uses thereof
|
JP6734774B2
(en)
|
2013-10-15 |
2020-08-05 |
ザ スクリプス リサーチ インスティテュート |
Peptide chimeric antigen receptor T cell switch and uses thereof
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
NZ758715A
(en)
|
2013-10-31 |
2023-01-27 |
Seattle Children’S Hospital Dba Seattle Children’S Res Institute |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
ES2767423T3
(en)
*
|
2014-01-13 |
2020-06-17 |
Hope City |
Chimeric antigen receptors (CARS) with mutations in the Fc spacer region and methods for their use
|
AU2015206040B2
(en)
|
2014-01-14 |
2018-11-01 |
Cellectis |
Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
|
US9694033B2
(en)
|
2014-01-24 |
2017-07-04 |
The Cleveland Clinic Foundation |
IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
|
CN111849912B
(en)
|
2014-02-14 |
2024-03-15 |
贝里坤制药股份有限公司 |
Method for activating T cells using inducible chimeric polypeptides
|
AU2015218365A1
(en)
|
2014-02-14 |
2016-09-01 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
AU2015219495B2
(en)
*
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
CA2977839C
(en)
|
2014-02-28 |
2022-07-26 |
The Royal Institution For The Advancement Of Learning / Mcgill University |
Tc-ptp inhibitors as apc activators for immunotherapy
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
KR101605421B1
(en)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
|
WO2015134877A1
(en)
|
2014-03-07 |
2015-09-11 |
Bellicum Pharmaceuticals, Inc. |
Caspase polypeptides having modified activity and uses thereof
|
EP3811970A1
(en)
|
2014-03-15 |
2021-04-28 |
Novartis AG |
Regulatable chimeric antigen receptor
|
KR102487608B1
(en)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
WO2015157299A2
(en)
|
2014-04-09 |
2015-10-15 |
Seattle Children's Hospital (Dba Seattle Children's Research Institute |
Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
|
MX2016013158A
(en)
|
2014-04-10 |
2017-04-27 |
Seattle Children's Hospital (Dba Seattle Children's Res Institute) |
Defined composition gene modified t-cell products.
|
KR20160145802A
(en)
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Chimeric antigen receptors (car) for use in therapy and methods for making the same
|
WO2015167766A1
(en)
|
2014-04-29 |
2015-11-05 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
|
EP3155018A4
(en)
|
2014-06-06 |
2018-01-10 |
The California Institute for Biomedical Research |
Constant region antibody fusion proteins and compositions thereof
|
WO2015191874A1
(en)
|
2014-06-12 |
2015-12-17 |
Children's National Medical Center |
Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use
|
EP3171882A1
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
TWI719942B
(en)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
Treatment of cancer using a cd33 chimeric antigen receptor
|
DK3177640T3
(en)
|
2014-08-08 |
2020-08-10 |
Univ Leland Stanford Junior |
HIGH AFFINITY PD-1 AGENTS AND USE PROCEDURES
|
WO2016025322A1
(en)
|
2014-08-09 |
2016-02-18 |
Purdue Research Foundation |
Design and development of neurokinin-1 receptor-binding agent delivery conjugates
|
JP2017524365A
(en)
|
2014-08-12 |
2017-08-31 |
アントフロゲネシス コーポレーション |
CAR-T cells engineered to home to lymph node B cell area, skin, or intestinal tract
|
CN112410363A
(en)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
anti-CD 123 Chimeric Antigen Receptor (CAR) for cancer therapy
|
AU2015312117A1
(en)
|
2014-09-02 |
2017-03-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
|
BR122024000360A2
(en)
|
2014-09-19 |
2024-02-27 |
City Of Hope |
NUCLEIC ACID MOLECULE, POPULATION OF HUMAN T CELLS TRANSDUCED BY A VECTOR COMPRISING AN EXPRESSION CASSETTE ENCODING A CHIMERIC ANTIGEN RECEPTOR AND ITS USE
|
WO2016054520A2
(en)
|
2014-10-03 |
2016-04-07 |
The California Institute For Biomedical Research |
Engineered cell surface proteins and uses thereof
|
WO2016057850A1
(en)
|
2014-10-09 |
2016-04-14 |
Seattle Children' S Hospital (Dba Seattle Children' S Research Institute) |
Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
|
CA2963478A1
(en)
|
2014-10-14 |
2016-04-21 |
Riptide Bioscience, Inc. |
Peptides having anti-inflammatory properties
|
CA2964392A1
(en)
|
2014-10-31 |
2016-05-06 |
Massachussetts Institute Of Technology |
Delivery of biomolecules to immune cells
|
CN107207615A
(en)
*
|
2014-11-05 |
2017-09-26 |
得克萨斯州大学系统董事会 |
The immune effector cell of genetic modification and the engineering cell for expanding immune effector cell
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3218492A4
(en)
|
2014-11-14 |
2018-10-10 |
Massachusetts Institute Of Technology |
Disruption and field enabled delivery of compounds and compositions into cells
|
WO2016081203A2
(en)
|
2014-11-17 |
2016-05-26 |
Cellectar Biosciences, Inc. |
Phospholipid ether analogs as cancer-targeting drug vehicles
|
JP2017537622A
(en)
|
2014-12-02 |
2017-12-21 |
ロジャー・ウィリアムズ・ホスピタル |
Methods and compositions for treating cancer
|
CN107429253B
(en)
|
2014-12-05 |
2021-11-05 |
希望之城公司 |
CS1 targeting chimeric antigen receptor modified T cell
|
EP3234144B1
(en)
|
2014-12-15 |
2020-08-26 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
EP3608408A1
(en)
|
2014-12-15 |
2020-02-12 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled activation or elimination of therapeutic cells
|
EP3240805A4
(en)
|
2014-12-15 |
2018-05-09 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
SG11201704084VA
(en)
|
2014-12-24 |
2017-06-29 |
Ucl Business Plc |
Cell
|
US10273300B2
(en)
|
2014-12-29 |
2019-04-30 |
The Trustees Of The University Of Pennsylvania |
Methods of making chimeric antigen receptor-expressing cells
|
JP6797803B2
(en)
|
2014-12-31 |
2020-12-09 |
セルジーン コーポレイション |
How to use natural killer cells to treat blood disorders, solid tumors, or infectious diseases
|
US9765330B1
(en)
|
2015-01-09 |
2017-09-19 |
Nant Holdings Ip, Llc |
Compositions and methods for reduction of allograft recognition and rejection
|
KR20170117450A
(en)
|
2015-02-18 |
2017-10-23 |
엔리벡스 테라퓨틱스 리미티드 |
Combination of immunotherapy and cytokine regulating therapy for cancer treatment
|
EP3262166A4
(en)
|
2015-02-24 |
2018-08-15 |
The Regents of The University of California |
Binding-triggered transcriptional switches and methods of use thereof
|
BR112017018770A2
(en)
|
2015-03-02 |
2018-04-17 |
Innovative Cellular Therapeutics CO., LTD. |
reduced immune tolerance induced by pd-l1
|
EP3270936A4
(en)
|
2015-03-17 |
2018-08-08 |
Chimera Bioengineering Inc. |
Smart car devices, de car polypeptides, side cars and uses thereof
|
EP3271463A4
(en)
|
2015-03-18 |
2018-08-01 |
Baylor College of Medicine |
Her2/erbb2 chimeric antigen receptor
|
US9717745B2
(en)
|
2015-03-19 |
2017-08-01 |
Zhejiang DTRM Biopharma Co. Ltd. |
Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
|
US20180214527A1
(en)
|
2015-03-26 |
2018-08-02 |
City Of Hope |
Bi-specific targeted chimeric antigen receptor t cells
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
GB201505305D0
(en)
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
WO2016168766A1
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized chimeric receptor t cell switches and uses thereof
|
US9574014B2
(en)
|
2015-05-15 |
2017-02-21 |
City Of Hope |
Chimeric antigen receptor compositions
|
US9636388B2
(en)
|
2015-05-19 |
2017-05-02 |
Morphogenesis, Inc. |
Multi-indication mRNA cancer immunotherapy
|
IL295224A
(en)
|
2015-05-28 |
2022-10-01 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
AU2016274989A1
(en)
|
2015-06-12 |
2017-11-02 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
US9663756B1
(en)
|
2016-02-25 |
2017-05-30 |
Flodesign Sonics, Inc. |
Acoustic separation of cellular supporting materials from cultured cells
|
CA2986604A1
(en)
|
2015-06-26 |
2016-12-29 |
University Of Southern California |
Masking chimeric antigen receptor t cells for tumor-specific activation
|
GB201514328D0
(en)
|
2015-08-12 |
2015-09-23 |
Sigmoid Pharma Ltd |
Compositions
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
WO2017035362A1
(en)
|
2015-08-26 |
2017-03-02 |
Achillion Pharmaceuticals, Inc. |
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
AU2016318773A1
(en)
|
2015-09-09 |
2018-04-12 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Genetic engineering of macrophages for immunotherapy
|
US9790467B2
(en)
|
2015-09-22 |
2017-10-17 |
Qt Holdings Corp |
Methods and compositions for activation or expansion of T lymphocytes
|
EP4108255A1
(en)
|
2015-10-05 |
2022-12-28 |
Precision Biosciences, Inc. |
Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
|
BR112018006991A2
(en)
|
2015-10-06 |
2018-10-16 |
Hope City |
psca-targeted chimeric antigen receptors
|
GB201518816D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
GB201518817D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
CN108697735A
(en)
|
2015-11-05 |
2018-10-23 |
希望之城公司 |
The method for being used to prepare the cell for adoptive T cell therapy
|
WO2017083274A1
(en)
|
2015-11-09 |
2017-05-18 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Novel rna-based vector system for transient and stable gene expression
|
TWI724056B
(en)
|
2015-11-19 |
2021-04-11 |
美商卡默森屈有限公司 |
Inhibitors of cxcr2
|
TWI734715B
(en)
|
2015-11-19 |
2021-08-01 |
美商卡默森屈有限公司 |
Modulators of chemokine receptors
|
CA3007473A1
(en)
|
2015-12-14 |
2017-06-22 |
Bellicum Pharmaceuticals, Inc. |
Dual controls for therapeutic cell activation or elimination
|
US9849092B2
(en)
|
2015-12-21 |
2017-12-26 |
Gholam A. Peyman |
Early cancer detection and enhanced immunotherapy
|
KR20180096788A
(en)
|
2016-01-08 |
2018-08-29 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Conditionally-active heterodimeric polypeptides and methods for their use
|
MY196175A
(en)
|
2016-01-11 |
2023-03-20 |
Univ Leland Stanford Junior |
Chimeric Proteins And Methods Of Regulating Gene Expression
|
WO2017123548A1
(en)
|
2016-01-14 |
2017-07-20 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
|
EP3912993A1
(en)
|
2016-02-05 |
2021-11-24 |
City of Hope |
Administration of engineered t cells for treatment of cancers in the central nervous system
|
GB201602571D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
GB201602563D0
(en)
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
CA3013479A1
(en)
|
2016-02-16 |
2017-08-24 |
Carl NOVINA |
Immunotherapy compositions and methods
|
WO2017143150A1
(en)
|
2016-02-19 |
2017-08-24 |
City Of Hope |
Bi-specific aptamer
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
SG10202104509PA
(en)
|
2016-03-19 |
2021-06-29 |
Exuma Biotech Corp |
Methods and compositions for transducing lymphocytes and regulated expansion thereof
|
AU2017238218A1
(en)
*
|
2016-03-22 |
2018-10-11 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
CA3019835A1
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
US11136405B2
(en)
|
2016-06-06 |
2021-10-05 |
Board Of Regents, The Unviersity Of Texas System |
BAFF-R antibodies and uses thereof
|
EP3464371A1
(en)
|
2016-06-06 |
2019-04-10 |
City of Hope |
Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof
|
GB201610512D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Chimeric antigen receptor
|
GB201610515D0
(en)
|
2016-06-16 |
2016-08-03 |
Autolus Ltd |
Cell
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CN115305229A
(en)
|
2016-07-13 |
2022-11-08 |
哈佛学院院长等 |
Antigen presenting cell mimetic scaffolds and methods of making and using same
|
KR102557818B1
(en)
|
2016-08-09 |
2023-07-20 |
시티 오브 호프 |
Chimeric poxvirus composition and use thereof
|
US9642906B2
(en)
|
2016-09-16 |
2017-05-09 |
Baylor College Of Medicine |
Generation of HPV-specific T-cells
|
WO2018075794A1
(en)
|
2016-10-19 |
2018-04-26 |
City Of Hope |
Use of triplex cmv vaccine in car t cell therapy
|
CA3040343A1
(en)
|
2016-10-19 |
2018-04-26 |
California Institute For Biomedical Research |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
US11116834B2
(en)
|
2016-10-19 |
2021-09-14 |
City Of Hope |
Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy
|
US10617720B2
(en)
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
WO2018080541A1
(en)
|
2016-10-31 |
2018-05-03 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
|
US20200095547A1
(en)
|
2016-12-02 |
2020-03-26 |
Darya ALIZADEH |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
MX2019006631A
(en)
|
2016-12-12 |
2019-11-12 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells.
|
WO2018111834A1
(en)
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
EP3558346A1
(en)
|
2016-12-21 |
2019-10-30 |
Danmarks Tekniske Universitet |
Antigen presenting scaffolds for immune-cell manipulation
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
CA3053534A1
(en)
|
2017-02-17 |
2018-08-23 |
Purdue Research Foundation |
Targeted ligand-payload based drug delivery for cell therapy
|
CN110582288A
(en)
*
|
2017-02-28 |
2019-12-17 |
恩多塞特公司 |
Compositions and methods for CAR T cell therapy
|
US20200405881A1
(en)
|
2017-03-06 |
2020-12-31 |
University Of Washington |
Cell based methods and compositions for therapeutic agent delivery and treatments using same
|
WO2018165194A1
(en)
|
2017-03-06 |
2018-09-13 |
University Of Washington |
Engineered cells and agent compositions for therapeutic agent delivery and treatments using same
|
AU2018235957B2
(en)
|
2017-03-16 |
2024-02-01 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
|
US11744862B2
(en)
|
2017-03-20 |
2023-09-05 |
City Of Hope |
CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis
|
WO2018213332A1
(en)
|
2017-05-17 |
2018-11-22 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy
|
AU2018312563A1
(en)
|
2017-08-01 |
2020-03-12 |
City Of Hope |
Anti-IL1RAP antibodies
|
WO2019033050A1
(en)
|
2017-08-11 |
2019-02-14 |
City Of Hope |
Bispecific antigen-binding molecule
|
CN112292138A
(en)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Methods of use of CAR T cells
|
EP3749695A4
(en)
|
2018-02-06 |
2021-12-29 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
WO2019165237A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
SG11202009975TA
(en)
|
2018-04-12 |
2020-11-27 |
Umoja Biopharma Inc |
Viral vectors and packaging cell lines
|
KR20210016353A
(en)
|
2018-04-27 |
2021-02-15 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
Rapamycin-resistant cells
|
CA3108778A1
(en)
|
2018-08-06 |
2020-02-13 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
|
US20210308267A1
(en)
|
2018-08-07 |
2021-10-07 |
Purdue Research Foundation |
Rejuvenation of car t cell
|
US20220017920A1
(en)
|
2018-11-21 |
2022-01-20 |
Umoja Biopharma, Inc. |
Multicistronic vector for surface engineering lentiviral particles
|
EP3993814A4
(en)
|
2019-07-05 |
2023-06-28 |
Purdue Research Foundation |
Design and efficient synthesis of lipid-fluorescein conjugates for car-t cell therapy
|
AU2020348781A1
(en)
|
2019-09-17 |
2022-04-14 |
Purdue Research Foundation |
Fibroblast activation protein (FAP)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
|
KR20220143634A
(en)
|
2019-10-16 |
2022-10-25 |
우모자 바이오파마 인코포레이티드 |
Retroviral Vectors for Universal Receptor Therapy
|
CN115697388A
(en)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
Bispecific transduction enhancers
|
US20230068879A1
(en)
|
2020-02-04 |
2023-03-02 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Anti-dinitrophenol chimeric antigen receptors
|
IL295074A
(en)
|
2020-02-04 |
2022-09-01 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
|
EP4114471A1
(en)
|
2020-03-06 |
2023-01-11 |
Purdue Research Foundation |
Methods, compounds, and compositions for modifying car-t cell activity
|
EP4182339A1
(en)
|
2020-07-16 |
2023-05-24 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
JP2023551220A
(en)
|
2020-11-20 |
2023-12-07 |
ウモジャ バイオファーマ インコーポレイテッド |
Vector systems and their use for delivering multiple polynucleotides
|
WO2022164935A1
(en)
|
2021-01-27 |
2022-08-04 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|